{
  "ticker": "PER",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971723",
  "id": "02971723",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250723",
  "time": "0846",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1ndzwshmjyk.pdf",
  "summary": "- **Preclinical data shows HMBD-002 combined with radiotherapy improves survival in SCCHN mouse models** (median survival 35.5 days vs. 27 days with radiotherapy alone; p < 0.05).  \n- **HMBD-002 targets VISTA**, a resistance mechanism upregulated by radiotherapy, enhancing immune response.  \n- **Potential clinical applications**: SCCHN (70,000 annual US cases), breast cancer, lung cancer, or melanoma.  \n\n*No direct capital markets or trading implications identified (R&D update only).*",
  "usage": {
    "prompt_tokens": 1540,
    "completion_tokens": 114,
    "total_tokens": 1654,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T22:59:37.869146"
}